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Abstract
Recommendations of first choice antibiotic therapy need to be based on actual antibiotic susceptibility data. We determined the
antibiotic susceptibility of E. coli in uncomplicated UTI among women and compared the results with 2004 and 2009. In 30
sentinel general practitioner practices of Nivel Primary Care database, urine samples were collected fromwomen with symptoms
of uncomplicated UTI. Patient characteristics, E. coli susceptibility, and ESBL production were analyzed. Six hundred eighty-
nine urine samples were collected;E. coliwas the most isolated uropathogen (83%). Antibiotic susceptibility was stable over time
except for ciprofloxacin (96% in 2004, 97% in 2009, and 94% in 2014; P < 0.05). The susceptibility to co-amoxiclav was 88%,
87%, and 92% in 2004, 2009, and 2014, respectively. The prevalence of ESBL-producing E. coli increased from 0.1% in 2004 to
2.2% in 2014 (P < 0.05). Regional differences in antibiotic susceptibility for co-trimoxazole were found being the highest in the
west (88%) and the lowest in the north (72%, P = 0.021). Ciprofloxacin susceptibility was related to antibiotic use in the past
3 months (97% no use versus 90% use, P = 0.002) and age > 70 years (P = 0.005). In 2014, prescription of fosfomycin increased
compared to 2009 (14.3% versus 5.6%) at the expense of co-amoxiclav, co-trimoxazole, and fluoroquinolones (P < 0.05). The
susceptibility percentages to most antimicrobial agents tested were stable over 10 years’ period although the prevalence of E. coli
and ESBLs significantly increased. Performance of a survey with regular intervals is warranted.
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Introduction
Most antibiotics in the Netherlands prescribed by general
practitioners (GPs) are for uncomplicated acute urinary tract
infections (UTI) in women [1, 2]. Escherichia coli (E. coli) is
the most frequently isolated microorganism, in up to 80% of
UTIs [3, 4]. Different studies report increased resistance of
E. coli in UTI, especially to beta-lactam antibiotics and
fluoroquinolones alone or in combination [5, 6]. Although
antibiotic resistance in the Netherlands is one of the lowest
worldwide, the prevalence of resistant microorganisms has
been increasing over time. Several studies describe an increas-
ing prevalence of extended spectrum β-lactamase (ESBL)-
producing Gram-negative rods and other highly resistant mi-
croorganism (HRMO) in the general population [7–9]. In ad-
dition, a high prevalence of resistant microorganisms has been
reported in specific populations such as travelers returning
from South East Asia [10], immigrants and refugees [11,
12], and patients with hospital-replaced home treatment [13],
as well as in livestock and agriculture [14–17]. Therefore, to
make an optimal empiric choice, it is important to determine
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with regular time intervals the antibiotic susceptibility in pop-
ulations commonly treated such as women with UTI.
For women with UTI, treatment guidelines are pub-
lished by the Dutch College of General Practitioners
(NHG). The choice of antimicrobial agents in the guide-
lines is based on national antimicrobial resistance (AMR)
data published in Nethmap [8]. These data are derived
from microbiological laboratories sending data to the
Na t i ona l I n s t i t u t e fo r Pub l i c Hea l t h and t h e
Environment. Yearly, this institute in close cooperation
with the SWAB (Dutch Working group on Antibiotic pol-
icy) reports national data on antibiotic consumption and
resistance in humans and animals in Nethmap and
MARAN, respectively [8]; based on the NHG guideline,
GPs should only submit urine for culture after failure of
first-line therapy [18]. However, antimicrobial resistance
of uropathogens isolated after therapy failure is not repre-
sentative for resistance rates in patients who were success-
fully treated. Since NHG guidelines for treatment of UTIs
should be based on the latter population, we determined
the AMR among women with complaints of an acute un-
complicated UTI visiting their GPs. Additionally, to de-
termine trends in susceptibility, AMR data of 2014 were
compared with the data collected in a similar population
in 2004 and 2009 [19, 20].
Patients and methods
Patients
From January 2014 to January 2015, all women of 11 years
and older with symptoms of dysuria, strangury, or urinary
frequency visiting 30 sentinel GP practices participating in
Nivel Primary Care Database were included [21]. This GP
network is nationally representative by regional distribution,
population density, practice features, GP, and patient charac-
teristics [21]. Exclusion criteria were symptoms of complicat-
ed UTI, fever > 38 °C, pregnancy, diabetes mellitus, urologi-
cal or nephrological problems, or immunodeficiency of any
kind, as were also antibiotic use and an episode of recurrent
UTI in the past 4 weeks.
To avoid bias concerning age, region, or medical history of
the patient, a maximum of 25 samples from any GP practice
was included during the study period.
Antibiotic prescription and UTI treatment history in the
past 3 months were recorded. A urine dipslide (Uriline,
56508; BioMérieux, Plainview, NY USA) was inoculated ac-
cording to the manufacturer’s instructions and sent for analy-
sis to the Centre for Infectious Diseases Research, Diagnostics
and laboratory Surveillance (IDS) of the National Institute for
Public health and the Environment (RIVM) in the
Netherlands.
Ethics approval and consent to participate
For patient-derived data from the NIVEL-PCD, ethics approv-
al via an METC was not needed, as explained in the “Privacy
statement NIVEL PCD”: Dutch law allows the use of elec-
tronic health records for research purposes under certain con-
ditions. According to this legislation, neither obtaining in-
formed consent from patients nor approval of a medical ethics
committee is obligatory for this type of observational studies
containing no directly identifiable data (Dutch Civil Law,
Ar t i c l e 7 :458 ; h t tp : / / www.du tchc iv i l l aw.com/
civilcodebook077.htm). This study has been approved by
the applicable governance bodies of NIVEL Primary Care
Database under nr. NZR00316.012.
Identification of the uropathogens and antibiotic
susceptibility testing
Bacterial growth on the dipslide was considered positive at ≥
105 cfu/mL. Growth of two or more bacterial species was
considered as contaminated and excluded. For identification
of the uropathogens, MALDI-TOFMS (MALDI Biotyper 3.0
van Bruker Daltonik GmbH, Bremen, Germany) was used.
The isolated microorganisms were stored at − 20 °C in
peptone/glycerol (30% w/v).
The antibiotic susceptibility of the isolates was performed
by disk diffusion according to the EUCAST criteria version
4.0 valid from Jan 1, 2014 as were the breakpoints of suscep-
tibility. The following antibiotics were tested: amoxicillin
(10 μg), co-amoxiclav (20/10 μg), trimethoprim (5 μg), co-
trimoxazole (1.25/23.75 μg), ciprofloxacin (5 μg)
nitrofurantoin (100 μg), and fosfomycin (200 μg).
Escherichia coli ATCC 35218 and ATCC 25922 were used
as control strains; breakpoints of susceptibility were according
to the EUCAST guidelines (http://www.eucast.org/clinical_
breakpoints/). The susceptibility of fosfomycin was tested
using the CLSI guidelines [22]. For detection of ESBL-
producing bacteria, putative colonies were streaked on
ChromID ESBL agar (Biomerieux) and confirmation of
ESBL production was performed according to the guideline
of the Dutch Society ofMedical Microbiology (NVMM) [23].
Comparison with the 2004 and 2009 data
The GP network, patient population, and methods were com-
parable to those described in the 2004 and 2009 studies, as
were the criteria for inclusion and exclusion of patients. The
microbiological analysis was performed in another laboratory
using the same methods as described for the 2004 and 2009
studies [19, 20, 22, 23]. The difference with the studies of
2004 and 2009 was the cutoff to define a UTI using a colony
count of 105 cfu/mL in the present study instead of 103 cfu/mL
in the previous ones. The EUCAST version used was version
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1.0 tentative for the period 2002–2009 and version 1.2 valid
from December 2010 in the previous studies and EUCAST
version 4.0 valid from January 2014 in the present one (http://
www.eucast.org/clinical_breakpoints/).
Regional differences
To analyze regional differences, we used the regional distri-
bution as used by Nivel [21]: North (provinces Groningen,
Friesland, and Drenthe), East (Overijssel, Gelderland, and
Flevoland), West (Utrecht, North-Holland, and South-
Holland), and South (Zeeland, North-Brabant, and Limburg)
[21].
Statistics
For the statistical analysis, SPSS 23.0 was used. The X2 test
was used to test the significance of associations within the
data.
Results
Baseline characteristics
During the study period, 689 urine samples were collected, of
which 535 (78%) were considered positive, 117 (17%) nega-
tive, and 37 (5%) were excluded because two or more bacteria
species were isolated. The median age of the total group of all
women was 57 years (range 11–101 years). Antibiotic use in
the past 3 months was the lowest in the age group 11–20 years
(17%) and increased to 46% in the age group of 70 years and
older. E. coli was the most frequently detected uropathogen
(83%), followed by Klebsiella pneumonia (5%) and
Klebsiella oxytoca (1.5%).
Antibiotic susceptibility of E. coli
Table 1 shows the susceptibility of E. coli in relation to three
determinants, i.e., antibiotic use in the past 3 months, age, and
region. Overall, the susceptibility ranges from 66% for amox-
icillin to 94% for ciprofloxacin and nearly 100% for both
nitrofurantoin and fosfomycin. For the various antibiotics, on-
ly three statistically significant associations were found be-
tween susceptibility and any of the three determinants. For
co-trimoxazole, the association with region was significant:
highest susceptibility in the west (88%) and lowest in the north
(72%, P = 0.021). For ciprofloxacin, the associations with
both previous antibiotic use and age were significant: less
susceptibility when previous antibiotic use (90% vs 97%)
(P = 0.002) and age > 71 (88%) (P = 0.005). The association
with region could not be tested for ciprofloxacin (violation of
chi-square test assumptions). Only 26, 3, and 2 isolates were
resistant to ciprofloxacin, nitrofurantoin, and fosfomycin,
respectively.
Of the 10 ESBL (2.2%)-positive isolates, nine were in the
age group 21 to 70 years, eight of them were from the Eastern
region.
Comparison with the survey of 2004 and 2009
The prevalence of E. coli isolates increased from 64%
(1013/1583) in 2004 to 72% (350/487) in 2009 [23], and to
83% (445/535) in 2014 (2004–2014, P < 0.05). No significant
differences in prevalence were observed for the other isolated
uropathogens (data not shown).
Antibiotic prescriptions in 2009 and 2014
There was a significant difference in empiric antibiotic pre-
scriptions between 2009 and 2014 (P < 0.05). The empirical
prescribing of nitrofurantoin and fosfomycin increased,
whereas the prescribing of the other antibiotics decreased
(Table 2). The antibiotic use between 1999 and 2014 fluctu-
ated between 10 and 11 DDD/1000 inhabitant-days [24].
In 2014, empirical antibiotic treatment was prescribed to
424 of the 689 patients (61.5%), and unknown in 70 (10.2%)
patients. The most frequently prescribed antibiotic was
nitrofurantoin (n = 293, 69%), followed by fosfomycin (n =
60, 14%) and ciprofloxacin (n = 25, 6%); the last two antibi-
otics were especially used in the elderly (> 51 years), 38% and
16%, respectively.
AMR from 2004 to 2014
Table 3 compares antibiotic susceptibilities of E. coli over
time. The susceptibility to co-amoxiclavwas in the 2004 study
88% and in 2009 87% compared to 92% in 2014. The suscep-
tibility for ciprofloxacin decreased significantly from 97% in
2009 to 94% in 2014 (X2 test; P < 0.05), but the decrease from
2004 (96%) to 2014 was not significant (X2 test; P = 0.10). No
other differences in susceptibility to the other agents over time
were found.
The prevalence of ESBL-producing E. coli increased over
time from 0.1% (1/1378) in 2004, to 1% (5/489) in 2009 and
to 2.2% (10/445) in 2014. The numbers involved do not allow
for testing the significance of this increase.
Discussion
In this study, we demonstrate that AMR did not increase over
the 10-year study period except the resistance to ciprofloxacin
and the prevalence of ESBL-producing E. coli. These results
are remarkable in this time of worldwide concern on the in-
crease in prevalence of antibiotic resistance [5, 6]. We also
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showed that the prevalence of E. coli isolated from urine sig-
nificantly increased in this time period and that fosfomycin
was more frequently prescribed at the expense of co-amoxi-
clav, co-trimoxazole, and fluoroquinolones.
In contrast to the global tendency of increasing AMR [25],
we showed only small changes in antibiotic susceptibility over
a 10-year time period. Both in Europe and on other continents,
AMR has been increasing in bacteria causing UTIs [5, 26–28].
The Netherlands has always reported relatively low AMR
rates and prudent antibiotic use [29]. Antibiotic consumption
has been directly related to AMR and the low antibiotic use in
the Netherlands may be an explanation for the stable AMR
[30–32]. It should be noted that the cultures were taken from
community-dwelling females with uncomplicated UTIs and a
presumed low antibiotic use and pressure.
The susceptibility of E. coli to co-amoxiclav increased
from 88% and 87% in the 2004 and 2009 studies to 92% in
the present one. In the last study, the EUCASTcriteria version
4.0 valid from January 2014 was used, whereas the two other
studies used the version 1.2. The main difference is the
breakpoint for susceptibility for co-amoxyclav being >
16 mm for all infections according to the version 1.2 and >
15 mm for UTI only is mentioned in the 4.0 version. The
version 1.2 does not mention the criterium “UTI only”; in
the 4.0 version, the breakpoint for all infections is > 18 mm.
Due to the different breakpoints used and depending on the
type of infections, it is difficult to assess whether the increase
in susceptibility is a real increase of just a virtual one. In other
European countries, a decrease of susceptibility has been de-
scribed [26]. In Ireland, the susceptibility of E. coli to co-
amoxiclav decreased from 90% in 2005 to 80% in 2014 in
community-dwelling patients with UTI [27]. Also in
Germany, co-amoxiclav susceptibility decreased from 92%
in 2014 to 75% in 2017 [28].
The decreased susceptibility of E. coli to ciprofloxacin was
in line with other studies [26–28]. In the EC0-SENS study, a
significant increase of resistance to ciprofloxacin from 2000 to
2014 was observed in different countries: in Germany from
2.2 to 20.2%, in Spain from 14.7 to 30.8%, in Sweden from
0.0 to 7.3%, and in the UK from 0.6 to 15.3% [26]. In Ireland,
resistance to ciprofloxacin increased from 5% in 2005 to
11.4% in 2014 [27]. An average increase in resistance per year
of 0.40% and 0.26% was found both in community-dwelling
and hospitalized patients, respectively [28]. According to the
Dutch NHG guidelines, ciprofloxacin is a last resort drug and
we showed that prescription rates decreased from 14% in
2004, 10% in 2009, to 5.9% in 2014 [18]. However, only a
small effect on susceptibility percentages could be demon-
strated; the E. coli susceptibility decreased from 96% in
2004 to 94% in 2014 (Table 3).
The rise in prevalence over time ofE. coliwas a remarkable
finding. Although the microbiological analysis of our last
Table 1 Antibiotic susceptibility of E. coli according to previous antibiotic use, age, and region
Amoxicillin Co-
amoxiclav
Trimethoprim Co-
trimoxazole*
Ciprofloxacin** Nitrofurantoin*** Fosfomycin***
Antibiotic use in the last 3 months susceptibility in number and (percentage)
Yes (N = 144) 87 (60%) 131 (91%) 108 (75%) 111 (77%) 129 (90%) 142 (99%) 142 (99%)
No (N = 282) 196 (70%) 261 (93%) 228 (81%) 235 (83%) 273 (97%) 281 (100%) 282 (100%)
Total (N = 426)i 283 (66%) 392 (92%) 336 (79%) 346 (81%) 402 (94%) 423 (99%) 424 (100%)
Age
11–20 (N = 28) 19 (68%) 25 (89%) 22 (79%) 23 (82%) 26 (93%) 28 (100%) 28 (100%)
21–50 (N = 136) 88 (65%) 129 (95%) 107 (79%) 112 (82%) 131 (96%) 136 (100%) 136 (100%)
51–70 (N = 155) 107 (69%) 143 (92%) 125 (81%) 127 (82%) 151 (97%) 153 (99%) 154 (99%)
> 70 (N = 126) 79 (63%) 110 (87%) 99 (79%) 101 (80%) 111 (88%) 125 (99%) 125 (99%)
Total (N = 445) 293 (66%) 407 (91%) 353 (79%) 363 (82%) 419 (94%) 442 (99%) 443 (100%)
Region
North (N = 82) 53 (65%) 73 (89%) 59 (72%) 59 (72%) 72 (88%) 81 (99%) 82 (100%)
East (N = 71) 50 (70%) 64 (90%) 55 (77%) 56 (79%) 64 (90%) 70 (99%) 71 (100%)
West (N = 184) 125 (68%) 169 (92%) 153 (83%) 161 (88%) 178 (97%) 184 (100%) 182 (99%)
South (N = 108) 65 (60%) 101 (94%) 86 (80%) 87 (81%) 105 (97%) 107 (99%) 108 (100%)
Total (N = 445) 293 (66%) 407 (91%) 353 (79%) 363 (82%) 419 (94%) 442 (99%) 443 (100%)
i In the case of antibiotic use in the last 3 months, 19 cases were unknown
*Association between susceptibility and region (P = 0.021)
**Associations between susceptibility and both previous antibiotic use (P = 0.002) and age (P = 0.005). For region, testing is inappropriate due to small
numbers
***Testing is inappropriate due to small numbers
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surveywas performed in another laboratory, the methods were
comparable. The 2009 survey showed already a significant
increase in prevalence of E. coli compared to 2004 [20]. The
prevalence of E. coli in UTI ranged from 76.7 to 84% in
different studies [27, 32, 33]. Cullen et al. also described an
increase of E. coli in an 11-year period of uncomplicated UTI
in community patients including fluctuation over time [33].
Different explanations were described in the literature, such as
rise in global temperature, seasonal peaks, and increasing age
of women with symptoms of UTI [34–36]. In this study, we
included patients during 6 months and did not observe influ-
ences of these seasons or age for the percentage of E. coli
isolates.
In Belgium, Heytens et al. found in a 20-year survey from
1995 to 2015 a higher percentage of E. coli in uncomplicated
UTI in post-menopausal women > 55 years of age compared
to the age group of 18–54 years, 89.9% versus 78.4%, respec-
tively [36]. Although the mean age in our study was 53.5 years
and 57%was 51 years or older, the prevalence of E. coli in the
age group 51 years and older was comparable to the younger
age group (82% versus 84%, respectively).
Other uropathogens such as K. pneumonia and K. oxytoca
were isolated less frequently. Risk factors for uropathogens
other than E. coli, like recurrent UTI, pregnancy, intensive
care hospitalization, presence of catheters, gender, age, and
diabetes mellitus, were exclusion criteria in our study except
age and gender [36, 37].
The regional differences in susceptibility of E. coli
(Table 1) were in contrast to the regional antibiotic prescrip-
tion of these agents (Table 2). The Northern and Eastern re-
gions are both adjacent to Germany, where, as shown in the
updated ECO-SENS study, resistance to ciprofloxacin in-
creased from 2.2 to 20.2%, and trimethoprim from 22.5 to
36.8% from 2000 to 2014 [26]. Social and economic traffic
between the regions and Germany is common [38] and geo-
graphical boundaries are not recognized by microorganisms
[39]. However, no data is available of E. coli susceptibility in
uncomplicated UTI in the community in the cross-border re-
gion. We found only limited regional data on antibiotic resis-
tance in Belgium or in Germany. The only available numbers
we found in Belgium were described in the relatively small
study of De Backer (2008) in the region Gent with 187 pa-
tients [40]. He described in his study from 1996 to 2006 a
stable prevalence of antibiotic susceptibility in urinary iso-
lates, i.e., a susceptibility of 83.3 to 86% for co-trimoxazole,
versus 86% in the South and 83% in the Western part of the
Netherlands (DenHeijer 2009). Van den Donk et al. compared
the prevalence of resistance in the cross-border region be-
tween Belgium, Germany, and the Netherlands among general
practitioners, nursing homes, and ICU isolates and found a
significant difference in prevalence of co-amoxiclav and cip-
rofloxacin resistance among all E. coli isolated between the
Netherlands and Belgium, i.e., 27% versus 21%, and 23% and
16%, respectively. No significant differences with Germany
were reported [41].
We found a regional difference in prevalence of ESBL-
positive isolates, where 8 out of 10 isolates all in the age
group of over 51 were from the Eastern region, close to
the border of Germany. The ECO-SENS study in 2014
reported an ESBL incidence of 10.5% [26]. Van den
Donk et al. (2012) showed a cross-border spread of
E. coli ST131 and CTX-M type ESBLs and a similar
prevalence of resistant E. coli in the Euregio Meuse
Rhine [42]. A recent study found the same ESBL CTX-
M15 genotype in cross-border hospitals in the Northern
part of the Netherlands and in Germany whereas in com-
munity isolates from the Netherlands, CTXM1 was found.
The results of this small study suggested cross-border
spread in clinical isolates. As no data was available from
German community strains, no conclusion could be
drawn concerning possible cross-border spread in the
community [43].
Table 2 Number (%) of empiric antibiotic prescriptions in the 2009 and
2014 surveys
2009 2014
N = 719 N = 419
Amoxicillin, N (%) 13 (1.8) 2 (0.5)
Co-amoxiclav, N (%) 54 (7.5) 18 (4.3)
Trimethoprim, N (%) 38 (5.3) 14 (3.3)
Co-trimoxazole, N (%) 27 (3.8) 3 (0.7)
Fluoroquinolones, N (%) 75 (10.4) 29 (6.9)
Nitrofurantoin, N (%) 472 (65.6) 293 (69.9)
Fosfomycin, N (%) 40 (5.6) 60 (14.3)
Fluoroquinolones; ciprofloxacin, norfloxacin
Azithromycin (n = 3) prescription excluded
Unknown (n = 2) in 2014
(X2 test; P < 0.05)
Table 3 Total E. coli susceptibility (%) in 2004 (Nys), 2009 (den
Heijer), and 2014
2004 2009 2014
N = 1378 N = 489 N = 445
Amoxicillin 923 (67) 323 (66) 293 (66)
Co-amoxiclav 1213 (88) 425 (87) 407 (92)
Trimethoprim 1061 (77) 396 (81) 353 (79)
Co-trimoxazole 1102 (80) 411 (84) 363 (82)
Ciprofloxacin* 1323 (96) 474 (97) 419 (94)
Nitrofurantoin** 1364 (99) 489 (100) 442 (99)
Fosfomycin** 1364 (99) 489 (100) 443 (99)
* Indicates a significant decreased antibiotic susceptibility between 2009
and 2014 for ciprofloxacin (X2 test; P < 0.05)
**Numbers too low for chi-squared test
2155Eur J Clin Microbiol Infect Dis (2019) 38:2151–2158
The prevalence of ESBL-positive E. coli isolates increased
from 0.1% in 2004 to 1.0% in 2009 and 2.2% in 2014. Several
reports also mentioned an increase in ESBL-producing E. coli
in community-acquired urinary tract infections. In Germany,
an increase was found, from 1.2 to 4.8% in 8 years’ time [26],
and more than 12% in a 10-year period in Ireland [27]. Of the
different risk factors described, such as recurrent UTI in the
past year, (recent) use of β lactam antibiotics or
fluoroquinolones, and traveling to Asia, Middle East, and
Africa [10, 44], we only had information for recurrent UTI.
The increase in nitrofurantoin and fosfomycin as empirical
prescription by the participating GPs was in line with the first
and second choice of antibiotic treatment of uncomplicated
UTI according to the NHG guidelines [18]. In addition, the
prescription of fluoroquinolones, co-trimoxazole, and co-
amoxiclav decreased significantly. The increase of fosfomycin
prescription was in line with the alteration from third to sec-
ond preference in 2013 of the national guideline. These data
underscore the adherence of GPs to the national guidelines
and indicate that national guidelines are valuable in antibiotic
stewardship [45].
Although fosfomycin shows promising results of low re-
sistance in UTI isolates [46] recently, a few studies describe
less clinical efficacy [47, 48]. Based on the literature and the
NHG guidelines, our recommendation is still nitrofurantoin as
first choice, followed by fosfomycin and trimethoprim as third
place if the isolated pathogen is susceptible. When more clin-
ical studies become available concerning the (decreased) clin-
ical efficacy of fosfomycin, the NHG guidelines might revise
the recommendations.
Strengths and limitations
The strength of our study is the national coverage, because the
participating general practices are nationally representative for
age, gender, regional distribution, and population density [21].
This enables us to compare (regional) differences in antibiotic
resistance of uropathogenic E. coli over time and to evaluate
whether the prescriptions of the GPs are in line with the rec-
ommendations of the NHG guideline for the treatment of un-
complicated UTI. The data we collected in our study is essen-
tial for the setup of guidelines for the treatment of uncompli-
cated UTI. Data in Nethmap are from patients after therapy
failure and not representative for successfully treated patients
and not suitable for the NHG guidelines [18].
A limitation of our study is the limited information regard-
ing lifestyle, known risk factors, like co-morbidity, hospitali-
zation, reinfection, or previous antibiotic use. More detailed
information as to patient and environmental characteristics is
recommended in the next survey. Also, our study is only rep-
resentative for the group of healthy women. Men and children
should be further investigated in a next survey to complete
national guidelines for GPs in treatment of UTI.
In conclusion, the susceptibility percentages of E. coli to
most antimicrobial agents isolated from uncomplicated UTI
among women were stable in the Netherlands over 10 years’
time, although the prevalence of E. coli and ESBL-producing
E. coli increased. These findings suggest that performing the
survey at a regular interval is warranted. The GPs’ empirical
prescription treatment was in line with the recommendations
of the national NHG guidelines.
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